Dapagliflozin Modulates MicroRNA Expression in Type 2 Diabetes Patients with Diabetic Nephropathy: A Retrospective Study

Deniz Yıldız Pehlivan; Hamit Yıldız; Gökhan Kaya

doi:10.58600/eurjther2520

Authors

Deniz Yıldız Pehlivan Department of Physiology, Graduate School of Health Sciences, Izmir Kâtip Celebi University, Izmir, Türkiye https://orcid.org/0000-0001-8127-2208
Hamit Yıldız Department of Internal Medicine, Faculty of Medicine, Gaziantep University, Gaziantep, Türkiye https://orcid.org/0000-0001-7858-5123
Gökhan Kaya Department of Internal Medicine, Ministry of Health, Pazarcik State Hospital, Kahramanmaras, Türkiye https://orcid.org/0009-0004-2668-2780

DOI:

https://doi.org/10.58600/eurjther2520

Keywords:

Type 2 diabetes mellitus, dapagliflozin, microRNA, diabetic nephropathy, microalbuminuria

Abstract

Objective: Diabetic nephropathy (DN) is one of the most serious microvascular complications of Diabetes Mellitus, the prevalence and mortality of which are increasing. Recently, microRNAs (miRNAs) used in the pathogenesis and diagnosis of many diseases have been identified. In this study investigate the relationship between albuminuria and miRNA levels in patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin, and to elucidate the potential nephroprotective effects of dapagliflozin through miRNA modulation.

Methods: This retrospective study included 47 T2DM patients (25 male, 22 female) with diabetic nephropathy (DN) treated with dapagliflozin. Blood samples were collected at baseline (day 0) and after approximately 60 days of treatment. Levels of miRNA-21, miRNA-141, and miRNA-377 were analyzed using real-time PCR. Clinical and laboratory parameters, including glucose, HbA1c, urine albumin and protein levels, were also assessed. Statistical analysis included the Wilcoxon signed-rank test and Spearman's rank correlation test.

Results: Significant decreases were observed in glucose, HbA1c, urinary protein, and albumin levels after dapagliflozin treatment (p<0.01). miRNA-21, miRNA-141, and miRNA-377 levels also decreased significantly following treatment (p<0.01). A positive correlation was found between day 0 miRNA-377 levels and day 0 serum glucose levels. A negative correlation was observed between day 0 miRNA-21 levels and day 60 HbA1c levels. No significant correlations were found between miRNA levels and urine albumin or protein levels.

Conclusion: Dapagliflozin treatment in T2DM patients with DN was associated with significant reductions in miRNA-21, miRNA-141, and miRNA-377 levels, alongside improvements in glycemic control and renal function markers. These findings suggest that dapagliflozin may exert its nephroprotective effects partly through modulation of DN-associated miRNAs. Dapagliflozin may be a therapeutic option to treat DN and may be an effective strategy to prevent kidney damage. Further research is warranted to elucidate the mechanisms underlying these effects and to explore the potential of miRNAs as biomarkers or therapeutic targets in DN management.

Metrics

Metrics Loading ...

References

American Diabetes A (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care. 37:S81-90. https://doi.org/10.2337/dc14-S081.

AKH Lim (2014) Diabetic nephropathy – Complications and treatment. Int J Nephrol Renovasc Dis. 7:361–381. https://doi.org/10.2147/IJNRD.S40172.

K Simpson, A Wonnacott, DJ Fraser, T Bowen (2016) MicroRNAs in diabetic nephropathy: From biomarkers to therapy. Curr Diab Rep. 16:1–7. https://doi.org/10.1007/s11892-016-0724-8.

VP Jayaseelan, P Arumugam (2020) Exosomal microRNAs as a promising theragnostic tool for essential hypertension. Hypertens Res. 43:74–75. https://doi.org/10.1038/s41440-019-0343-2.

D. Sekar (2018) Comment on the potential role of microRNAs in hypertension. J Hum Hypertens. 32:639–640. https://doi.org/10.1038/s41371-018-0104-8.

V Tsimihodimos, TD Filippatos, S Filippas-Ntekouan, M Elisaf (2017) Renoprotective effects of SGLT2 inhibitors: Beyond glucose reabsorption inhibition. Curr Vasc Pharmacol. 15:96–102. https://doi.org/10.2174/1570161114666161007163426.

C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, M Mattheus, OE Johansen, HJ Woerle, UC Broedl, B Zinman (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 375:323–334. https://doi.org/10.1056/nejmoa1515920.

A Lardaro, L Quarta, S Pagnotta, G Sodero, S Mariani, M Del Ben, G Desideri, E Ettorre, F Baratta (2024) Impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) therapy on dementia and cognitive decline. Biomedicines. 12:1750. https://doi.org/10.3390/biomedicines12081750.

K Kobayashi, M Toyoda, N Hatori, H Sakai, T Furuki, K Sato, Y Terauchi, K Tamura, A Kanamori (2022) Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Sci Rep. 12:16106. https://doi.org/10.1038/s41598-022-20313-5.

IG Albayrak (2022) miRNAs : Biogenesis, analysis methods and biomarker potential. Van Sag Bil Derg. 15:95–102. https://doi.org/https://doi.org/10.52976/vansaglik.952243.

Q Cao, XM Chen, C Huang, CA Pollock (2019) MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. FASEB Bioadv. 1:375–388. https://doi.org/10.1096/fba.2018-00064.

DP Bartel (2009) MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. https://doi.org/10.1016/j.cell.2009.01.002.

LB Nielsen, C Wang, K Sørensen, CH Bang-Berthelsen, L Hansen, MLM Andersen, P Hougaard, A Juul, CY Zhang, F Pociot, HB Mortensen (2012) Circulating levels of MicroRNA from children with newly diagnosed type 1 diabetes and healthy controls: Evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res. 1–7. https://doi.org/10.1155/2012/896362.

A Villard, L Marchand, C Thivolet, S Rome (2015) Diagnostic value of cell-free circulating micrornas for obesity and type 2 diabetes: A meta-analysis. J Mol Biomark Diagn. 6:1–21. https://doi.org/10.4172/2155-9929.1000251.

Z Yang, H Chen, H Si, X Li, X Ding, Q Sheng, P Chen, H Zhang (2014) Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 51:823–831. https://doi.org/10.1007/s00592-014-0617-8.

C Zhao, J Dong, T Jiang, Z Shi, B Yu, Y Zhu, D Chen, J Xu, R Huo, J Dai, Y Xia, S Pan, Z Hu, J Sha (2011) Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One. 6:e23925. https://doi.org/10.1371/journal.pone.0023925.

A Ismail, HA El-Mahdy, MG Eldeib, AS Doghish (2023) miRNAs as cornerstones in diabetic microvascular complications. Mol Genet Metab. 138:1–11. https://doi.org/10.1016/j.ymgme.2022.106978.

J Szostak, A Gorący, D Durys, P Dec, A Modrzejewski, A Pawlik (2023) The role of MicroRNA in the pathogenesis of diabetic nephropathy. Int J Mol Sci. 24:6214. https://doi.org/10.3390/ijms24076214.

ZW Zhang, MQ Tang, W Liu, Y Song, MJ Gao, P Ni, DD Zhang, Q gui Mo, BQ Zhao (2024) Dapagliflozin prevents kidney podocytes pyroptosis via miR-155-5p/HO-1/NLRP3 axis modulation. Int Immunopharmacol. 131:111785. https://doi.org/10.1016/j.intimp.2024.111785.

MK Sulaiman (2019) Diabetic nephropathy: Recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 11:1–5. https://doi.org/10.1186/s13098-019-0403-4.

SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, MG Silverman, TA Zelniker, JF Kuder, SA Murphy, DL Bhatt, LA Leiter, DK McGuire, JPH. Wilding, CT Ruff, IAM Gause-Nilsson, M Fredriksson, PA Johansson, A-M Langkilde, MS Sabatine (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 380:347–357. https://doi.org/10.1056/nejmoa1812389.

B Zinman, C Wanner, J Lachin, D Fitchett, E Bluhmki, S Hantel, M Mattheus, D Biomath, T Devins, OE Johansen, HJ Woerle, UC Broedl, SE Inzucchi (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720.

S Okovityy, D Ivkin, M Krasnova, A Karpov, G Ivanova, O Beresneva, E Kashine, Z Mikhail, O Galkina, M Parastaeva (2020) Can empagliflozin be a candidate for the role of a universal cardio- and nephroprotective drug in chronic heart failure without diabetes mellitus? Nephrology Dialysis Transplantation. 35:291. https://doi.org/10.1093/ndt/gfaa144.p0149.

SM Al-Tantawy, SM Eraky, LA Eissa (2023) Promising renoprotective effect of gold nanoparticles and dapagliflozin in diabetic nephropathy via targeting miR-192 and miR-21. J Biochem Mol Toxicol. 37:e23430. https://doi.org/10.1002/jbt.23430.

T Wang, H Zhu, S Yang, X Fei (2019) Let‑7a‑5p may participate in the pathogenesis of diabetic nephropathy through targeting HMGA2. Mol Med Rep. 19:4229–4237. https://doi.org/10.3892/mmr.2019.10057.

S Deshpande, M Abdollahi, M Wang, L Lanting, M Kato, R Natarajan (2018) Reduced autophagy by a microRNA-mediated signaling cascade in diabacetes-induced renal glomerular hypertrophy. Sci Rep. 8:1–13. https://doi.org/10.1038/s41598-018-25295-x.

Q Wang, Y Wang, AW Minto, J Wang, Q Shi, X Li, RJ Quigg (2008) MicroRNA‐377 is up‐regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 22:4126–4135. https://doi.org/10.1096/fj.08-112326.

C Wang, S Wan, T Yang, D Niu, A Zhang, C Yang, J Cai, J Wu, J Song, CY Zhang, C Zhang, J Wang (2016) Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci Rep. 6:1–9. https://doi.org/10.1038/srep20032.

L Wu, Q Wang, F Guo, X Ma, H Ji, F Liu, Y Zhao, G Qin (2016) MicroRNA-27a induces mesangial cell injury by targeting of PPARγ, and its in vivo knockdown prevents progression of diabetic nephropathy. Scientific Reports. 6:1–12. https://doi.org/10.1038/srep26072.

X Bai, J Geng, Z Zhou, J Tian, X Li (2016) MicroRNA-130b improves renal tubulointerstitial fibrosis via repression of Snail-induced epithelial-mesenchymal transition in diabetic nephropathy. Scientific Reports. 6:1–16. https://doi.org/10.1038/srep20475.

F Han, S Wang, Y Chang, C Li, J Yang, Z Han, B Chang, B Sun, L Chen (2018) Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA-137/Notch1 pathway. J Cell Physiol. 233:2225–2237. https://doi.org/10.1002/jcp.26092.

M Fouad, I Salem, K Elhefnawy, N Raafat, A Faisal (2020) MicroRNA-21 as an early marker of nephropathy in patients with type 1 diabetes. Indian J Nephrol. 30:21–25. https://doi.org/10.4103/ijn.IJN.

J Tang, D Yao, H Yan, X Chen, L Wang, H Zhan (2019) The role of microRNAs in the pathogenesis of diabetic nephropathy. Int J Endocrinol. 1:1–8. https://doi.org/10.1155/2019/8719060.

Z Zhang, H Peng, J Chen, X Chen, F Han, X Xu, X He, N Yan (2009) MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 583:2009–2014. https://doi.org/10.1016/j.febslet.2009.05.021.

M Kölling, T Kaucsar, C Schauerte, A Hübner, A Dettling, JK Park, M Busch, X Wulff, M Meier, K Scherf, N Bukosza, G Szénási, M Godó, A Sharma, M Heuser, P Hamar, C Bang, H Haller, T Thum, JM Lorenzen (2017) Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice. Mol Ther. 25:165–180. https://doi.org/10.1016/j.ymthe.2016.08.001.

X Xu, AJ Kriegel, Y Liu, K Usa, D Mladinov, H Liu, Y Fang, X Ding, M Liang (2012) Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int. 82:1167–1175. https://doi.org/10.1038/ki.2012.241.

J-Y Wang, Y-B Gao, N Zhang, D-W Zou, P Wang, Z-Y Zhu, J-Y Li, S-N Zhou, S-C Wang, Y-Y Wang, J-K Yang (2014) MiR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol. 392:163–172. https://doi.org/10.1016/j.mce.2014.05.018.

T Sun, Y Liu, L Liu, F Ma (2020) MicroRNA-544 attenuates diabetic renal injury via suppressing glomerulosclerosis and inflammation by targeting FASN. Gene. 723:1–9. https://doi.org/10.1016/j.gene.2019.143986.

Y Li, D Huang, L Zheng, H Cao, Z Fan (2019)Effect of microRNA-141 on the development of diabetic nephropathy through regulating AKT/AMPK signaling pathway by targeting insulin receptor substrate 2. J Cell Biochem. 120:8008–8015. https://doi.org/10.1002/jcb.28078.

B Wang, P Koh, C Winbanks, MT Coughlan, A McClelland, A Watson, K Jandeleit-Dahm, WC Burns, MC Thomas, ME Cooper, P Kantharidis (2011) MiR-200a prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes. 60:280–287. https://doi.org/10.2337/db10-0892.

M Xiong, L Jiang, Y Zhou, W Qiu, L Fang, R Tan, P Wen, J Yang (2012) The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 302:369–379. https://doi.org/10.1152/ajprenal.00268.2011.

MH El-Samahy, AA Adly, YI Elhenawy, EA Ismail, SA Pessar, MES Mowafy, MS Saad, HH Mohammed (2018) Urinary miRNA-377 and miRNA-216a as biomarkers of nephropathy and subclinical atherosclerotic risk in pediatric patients with type 1 diabetes. J Diabetes Complications. 32:185–192. https://doi.org/10.1016/j.jdiacomp.2017.10.014.

Y Yang, L Xiao, J Li, YS Kanwar, F Liu, L Sun (2013) Urine miRNAs: Potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses. 81:274–278. https://doi.org/10.1016/j.mehy.2013.04.031.